乳腺癌幸存者绝经症状及相关临床问题的管理
本文综述随机对照临床试验、观察性研究、循证指南和专家意见,为乳腺癌后女性绝经症状的管理提供指导。乳腺癌后女性一般不应接受绝经激素治疗或替勃龙,应优化生活方式;中重度症状者可受益于心脑行为或非激素药物治疗。
要点
- 乳腺癌后女性一般不应接受绝经激素治疗或替勃龙,应优化生活方式。
- 中重度血管舒缩症状者可受益于心脑行为或非激素药物治疗。
- 低剂量阴道雌激素可能刺激隐匿乳腺癌细胞,尤其芳香化酶抑制剂使用者一般不推荐。
核心结论
- 非激素选择和疗法可用于治疗乳腺癌诊断后雌激素缺乏症状和临床问题,个体化治疗至关重要。
研究设计与样本
- 综述随机对照临床试验、观察性研究、循证指南和专业学会专家意见。
主要发现
- 选择性5-羟色胺/去甲肾上腺素再摄取抑制剂和加巴喷丁类药改善血管舒缩症状和生活质量。
- 低剂量阴道雌激素吸收量小,血药浓度保持在绝经后正常范围,但可能刺激隐匿乳腺癌细胞。
- 阴道脱氢表雄酮和口服奥培米芬已获批治疗性交痛,但乳腺癌后安全性尚未确立。
- 阴道激光治疗用于外阴阴道萎缩,但缺乏假手术对照研究的疗效证据。
关键数值与推荐
- 乳腺癌后女性一般不应接受绝经激素治疗或替勃龙,应优化生活方式。
- 中重度症状者可受益于心脑行为或非激素药物治疗。
- 低剂量阴道雌激素一般不推荐,尤其芳香化酶抑制剂使用者。
- 阴道脱氢表雄酮和口服奥培米芬已获批治疗性交痛,但乳腺癌后安全性尚未确立。
临床怎么用
- 乳腺癌后女性一般不应接受绝经激素治疗或替勃龙,应优化生活方式。
- 中重度血管舒缩症状者可受益于心脑行为或非激素药物治疗。
- 低剂量阴道雌激素一般不推荐,尤其芳香化酶抑制剂使用者。
- 阴道脱氢表雄酮和口服奥培米芬已获批治疗性交痛,但乳腺癌后安全性尚未确立。
局限性
- 低剂量阴道雌激素的安全性研究不足。
- 阴道激光治疗缺乏假手术对照研究的疗效证据。
- 阴道脱氢表雄酮和口服奥培米芬乳腺癌后安全性尚未确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Review evidence to guide management of menopausal signs and symptoms in women after breast cancer and make recommendations accordingly. EVIDENCE: Randomized controlled clinical trials, observational studies, evidence-based guidelines, and expert opinion from professional societies. BACKGROUND: Symptoms and clinical problems associated with estrogen depletion-sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis-confront the estimated 9.3 million breast cancer survivors globally. RECOMMENDATIONS: Following breast cancer, women should not generally be treated with menopausal hormone therapy or tibolone but should optimize lifestyle. Women with moderate to severe symptoms may benefit from mind-brain behavior or nonhormone, pharmacologic therapy. The selective serotonin/noradrenaline reuptake inhibitors and gabapentenoid agents improve VMS and quality of life. For osteoporosis, nonhormonal agents are available. Treatment of VVA remains an area of unmet need. Low-dose vaginal estrogen is absorbed in small amounts with blood levels remaining within the normal postmenopausal range but could potentially stimulate occult breast cancer cells, and although poorly studied, is not generally advised, particularly for those on aromatase inhibitors. Intravaginal dehydroepiandrosterone and oral ospemiphene have been approved to treat dyspareunia, but safety after breast cancer has not been established. Vaginal laser therapy is being used for VVA but efficacy from sham-controlled studies is lacking. Therapies undergoing development include lasofoxifene, neurokinin B inhibitors, stellate ganglion blockade, vaginal testosterone, and estetrol. CONCLUSIONS: Nonhormone options and therapies are available for treatment of estrogen depletion symptoms and clinical problems after a diagnosis of breast cancer. Individualization of treatment is essential.
引用
- Santen RJ, Stuenkel CA, Davis SR, et al. Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. J Clin Endocrinol Metab. 2017. PMID: 28934376. doi:10.1210/jc.2017-01138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。